88 related articles for article (PubMed ID: 30422889)
1. Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.
Lezama-Martinez D; Flores-Monroy J; Fonseca-Coronado S; Hernandez-Campos ME; Valencia-Hernandez I; Martinez-Aguilar L
J Cardiovasc Pharmacol; 2018 Dec; 72(6):291-295. PubMed ID: 30422889
[TBL] [Abstract][Full Text] [Related]
2. Four-week inhibition of the renin-angiotensin system in spontaneously hypertensive rats results in persistently lower blood pressure with reduced kidney renin and changes in expression of relevant gene networks.
Byars SG; Prestes PR; Suphapimol V; Takeuchi F; De Vries N; Maier MC; Melo M; Balding D; Samani N; Allen AM; Kato N; Wilkinson-Berka JL; Charchar F; Harrap SB
Cardiovasc Res; 2024 May; 120(7):769-781. PubMed ID: 38501595
[TBL] [Abstract][Full Text] [Related]
3. The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats.
Emanueli C; Chao J; Regoli D; Chao L; Ni A; Madeddu P
Br J Pharmacol; 1999 Apr; 126(8):1769-76. PubMed ID: 10372819
[TBL] [Abstract][Full Text] [Related]
4. Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.
Jiang X; Eales JM; Scannali D; Nazgiewicz A; Prestes P; Maier M; Denniff M; Xu X; Saluja S; Cano-Gamez E; Wystrychowski W; Szulinska M; Antczak A; Byars S; Skrypnik D; Glyda M; Król R; Zywiec J; Zukowska-Szczechowska E; Burrell LM; Woolf AS; Greenstein A; Bogdanski P; Keavney B; Morris AP; Heagerty A; Williams B; Harrap SB; Trynka G; Samani NJ; Guzik TJ; Charchar FJ; Tomaszewski M
Eur Heart J; 2020 Dec; 41(48):4580-4588. PubMed ID: 33206176
[TBL] [Abstract][Full Text] [Related]
5. STRUCTURAL CHARACTERISTICS AND ANTIHYPERTENSIVE EFFECTS OF ANGIOTENSIN-I-CONVERTING ENZYME INHIBITORY PEPTIDES IN THE RENIN-ANGIOTENSIN AND KALLIKREIN KININ SYSTEMS.
Manoharan S; Shuib AS; Abdullah N
Afr J Tradit Complement Altern Med; 2017; 14(2):383-406. PubMed ID: 28573254
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats.
Corrêa BSG; de Barros S; Vaz JB; Peres MA; Uchiyama MK; da Silva AA; Furukawa LNS
Physiol Rep; 2023 Feb; 11(3):e15598. PubMed ID: 36750199
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression.
Cheng HF; Wang JL; Zhang MZ; Miyazaki Y; Ichikawa I; McKanna JA; Harris RC
J Clin Invest; 1999 Apr; 103(7):953-61. PubMed ID: 10194467
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of cardiac function and activation of anti-inflammatory vasoactive peptides expression in the rat myocardium by low level laser therapy.
Manchini MT; Serra AJ; Feliciano Rdos S; Santana ET; Antônio EL; de Tarso Camillo de Carvalho P; Montemor J; Crajoinas RO; Girardi AC; Tucci PJ; Silva JA
PLoS One; 2014; 9(7):e101270. PubMed ID: 24991808
[TBL] [Abstract][Full Text] [Related]
9. ACE2/ACE imbalance mediates bisphenol A-induced lung injury in Wistar rats: Results from captopril versus losartan histo-biochemical study.
Morsi AA; Mersal EA; Abdelmoneim AM; Faruk EM; Sofii MM; Sadek NA; Ibrahim KE; Aljanfawe HJ; Elmadhoun I; Mubarak W; Mahmoud MM; Salim MS
Heliyon; 2023 Nov; 9(11):e22056. PubMed ID: 38027817
[TBL] [Abstract][Full Text] [Related]
10. Insights into the associative role of hypertension and angiotensin II receptor in lower urinary tract dysfunction.
Shimizu S
Hypertens Res; 2024 Apr; 47(4):987-997. PubMed ID: 38351189
[TBL] [Abstract][Full Text] [Related]
11. The antihypertensive action of C-phycocyanin is related to the prevention of angiotensin II-caused vascular dysfunction in chronic kidney disease.
Tapia-Martínez JA; Centurión D; Franco-Colin M; Sánchez-López A; Beltran-Ornelas JH; Silva-Velasco DL; Franco PR; Blas-Valdivia V; Cano-Europa E
Hypertens Res; 2024 Apr; 47(4):1024-1032. PubMed ID: 38238510
[TBL] [Abstract][Full Text] [Related]
12. The epigenetic legacy of renin-angiotensin system inhibition in preventing hypertension.
Nosalski R; Lemoli M
Cardiovasc Res; 2024 May; 120(7):675-677. PubMed ID: 38634882
[No Abstract] [Full Text] [Related]
13. Rapeseed protein-derived peptides, LY, RALP, and GHS, modulates key enzymes and intermediate products of renin-angiotensin system pathway in spontaneously hypertensive rat.
He R; Yang YJ; Wang Z; Xing CR; Yuan J; Wang LF; Udenigwe C; Ju XR
NPJ Sci Food; 2019; 3():1. PubMed ID: 31304273
[TBL] [Abstract][Full Text] [Related]
14. Why isn't the angiotensin type 1 receptor a target in cancer?
Vinson GP
Oncotarget; 2017 Mar; 8(12):18618-18619. PubMed ID: 28423631
[No Abstract] [Full Text] [Related]
15. ACE2 as a potential therapeutic target for pandemic COVID-19.
Chatterjee B; Thakur SS
RSC Adv; 2020 Oct; 10(65):39808-39813. PubMed ID: 35515386
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.
Kai H; Kai M; Niiyama H; Okina N; Sasaki M; Maeda T; Katoh A
Hypertens Res; 2021 Aug; 44(8):955-968. PubMed ID: 33750913
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
Oz M; Lorke DE; Kabbani N
Pharmacol Ther; 2021 May; 221():107750. PubMed ID: 33275999
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies.
Pathangey G; Fadadu PP; Hospodar AR; Abbas AE
Am J Physiol Lung Cell Mol Physiol; 2021 Mar; 320(3):L301-L330. PubMed ID: 33237815
[TBL] [Abstract][Full Text] [Related]
19. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.
Dambha-Miller H; Albasri A; Hodgson S; Wilcox CR; Khan S; Islam N; Little P; Griffin SJ
BMJ Open; 2020 Sep; 10(9):e040644. PubMed ID: 32928868
[TBL] [Abstract][Full Text] [Related]
20. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
Reynolds HR; Adhikari S; Pulgarin C; Troxel AB; Iturrate E; Johnson SB; Hausvater A; Newman JD; Berger JS; Bangalore S; Katz SD; Fishman GI; Kunichoff D; Chen Y; Ogedegbe G; Hochman JS
N Engl J Med; 2020 Jun; 382(25):2441-2448. PubMed ID: 32356628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
